DLDengtang Liu

Dengtang Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dengtang Liu has a total of 168 co-authors. Here are the top co-authors by number of shared publications:

  • Kaiming Zhuo

    Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    20 shared publications
  • Qiong Xiang

    Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    20 shared publications
  • Zhaolin Zhai

    Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    13 shared publications
  • Xuan Li

    Shanghai Jiao Tong University School of Medicine

    11 shared publications
  • Tianhao Gao

    Shanghai Jiao Tong University School of Medicine

    9 shared publications
  • Suzhen Zhang

    First-episode Schizophrenia and Early Psychosis Program, Division of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    8 shared publications

Latest Publications

  • Open Access

    Nucleus Accumbens-Anterior Limb of Internal Capsule Deep Brain Stimulation for Treatment-Resistant Schizophrenia: An Open-label Pilot Study

    by Chang Lu, Xin Zhang, Zhaolin Zhai, Jingxin Xue, Yuqing Zhao, Qiong Xiang, Kaiming Zhuo, Yifeng Shen, Huiqin Han, Hongbing Lei, et al.

    We conducted an open-label pilot study of bilateral nucleus accumbens-anterior limb of the internal capsule (NAc-ALIC) deep brain stimulation (DBS) in three patients with treatment-resistant schizophrenia (TRS). Clinical symptoms, global functioning, cognition, stimulation parameters and intracranial local field potential (LFP) were assessed over 24 weeks. Two patients met the prespecified clinical response criterion, defined as a ≥40% reduction in Positive and Negative Syndrome Scale (PANSS) total score, by week 8 and showed PANSS reductions of 69.0% and 69.4%, respectively, at week 24. The third patient showed a 18.7% reduction at week 24. Responders showed improvements in global functioning and selected cognitive domains. Longitudinal LFP recordings revealed increased gamma-band relative power and reduced theta-band activity in responders, whereas these changes were less consistent in the non-responder. DBS was generally well tolerated, with transient stimulation-related adverse effects resolving after reprogramming. These findings provide preliminary clinical evidence supporting further investigation of NAc-ALIC DBS in TRS and suggest that individualized programming and intracranial physiological measures may contribute to the identification of treatment-response signatures. Registration: NCT06112067 in ClinicalTrial.gov

  • Open Access

    Predicting functional remission after antipsychotic discontinuation: a real-world study in schizophrenia – ERRATUM

    by Chang Lu, Yuke Dong, Zhaolin Zhai, Tianhao Gao, Mengyi Luo, Di Chang, Jing Chen, Jingxin Xue, Yuqing Zhao, Qiong Xiang, et al.

  • Open Access

    Predicting functional remission after antipsychotic discontinuation: a real-world study in schizophrenia

    by Chang Lu, Yuke Dong, Zhaolin Zhai, Tianhao Gao, Mengyi Luo, Di Chang, Jing Chen, Jingxin Xue, Yuqing Zhao, Qiong Xiang, et al.

    Background: This real-world study aimed to characterize patients with schizophrenia who achieve sustained good functional outcomes after antipsychotic discontinuation and to develop the Functional Remission in Schizophrenia after Antipsychotic Discontinuation (FURSAD) predictive model. Methods: We retrospectively identified individuals aged 18–65 years with schizophrenia (ICD-10) from the Shanghai Mental Health Center discharge database. Patients who discontinued antipsychotics for ≥1 year were classified as functional remission (FR) or functional non-remission (FNR) based on functioning assessments. Sociodemographic, clinical, and treatment-related data were extracted blindly from hospital records and structured interviews. Results: Among 4,166 discharged patients screened, 180 met the inclusion criteria (FR: 116; FNR: 64). Six independent predictors were identified: total disease course, Clinical Global Impression-Severity (CGI-S) score, Positive and Negative Syndrome Scale (PANSS) emotional distress subscale score, use of first-generation antipsychotics, discontinuation due to treatment benefits, and discontinuation due to lack of insight. The logistic regression model showed strong predictive performance (AUC = 0.867, 95% CI 0.813–0.921), with 82.8% sensitivity and 81.9% specificity. Internal validation was performed via 10-fold cross-validation. Conclusion: Discontinuation motives and illness trajectory are relevant in predicting long-term functional outcomes. A limitation is that a substantial number of patients could not be recontacted or declined participation, which may introduce selection bias. The FURSAD nomogram may help clinicians estimate the probability of FR 4.5 years post-antipsychotic discontinuation in patients previously on antipsychotics for ≥3 years.


  • Open Access

    Efficacy and Safety of Risperidone Microspheres for Injection (II) in Patients With Schizophrenia Spectrum Disorders: A Prospective, Single-Arm, Multicenter Real-World Study

    by Wei Li, Jinghui Tong, Xiaoxiao Gao, Hu Deng, Zezhi Li, Junhong Zhu, Jiahong Liu, Yanchi Zhang, Dengtang Liu, Xiaobin Zhang, et al.

    Background: Long-acting injectable (LAI) antipsychotics improve adherence and promote long-term recovery in schizophrenia spectrum disorders (SSD). Risperidone Microspheres for Injection (II) (RMI-II), a novel LAI formulation, offers rapid symptom control with a 2-week dosing interval. However, real-world evidence regarding its efficacy and safety remains limited. Methods: A prospective, single-arm, multicenter study was conducted across 15 Chinese research centers. Eligible patients (n = 228) met DSM-5 criteria for SSD, had a Positive and Negative Syndrome Scale (PANSS) total score ≥70, and were followed for 12 weeks. Patients received RMI-II (25–50 mg/2 weeks) via intramuscular injection. Results: Among 228 patients (50.88% male, mean age [37.00 ± 12.82] years) receiving RMI-II, the PANSS total score decreased significantly by 14.02 (3.22, 24.85) at week 2 (p < 0.001) and 38.28 (19.02, 51.34) at week 12 (p < 0.001). At week 2, 37.1% patients achieved clinical response (defined as ≥20% reduction in PANSS total score), and this proportion increased to 83.7% by week 12. By the end of the 12-week treatment, the clinical remission rate (defined as scores ≤3 on PANSS items P1, P2, P3, N1, N4, N6, G5, and G9) was 68.9%. The Clinical Global Impression–Severity Scale score improved from a baseline moderate-to-severe level 5.0 (5.0, 6.0) to a mild-to-moderate level 3.0 (2.0, 4.0). Adverse events occurred in 15.35% of patients, with hyperprolactinemia (1.3%) and extrapyramidal symptoms (1.3%) being most common. Conclusions: RMI-II appeared to be effective and well-tolerated in reducing acute psychotic symptoms. These findings suggest it may represent an additional therapeutic option for SSD. Clinical Trial Registration: No: ChiCTR2200066865, 20 December 2022, https://www.chictr.org.cn/showproj.html?proj=183302.

  • Cell type-specific transcriptional features associated with gray matter volume alterations in schizophrenia with predominantly negative symptoms

    by Xinping Kuai, Suzhen Zhang, Tianhao Gao, Qiong Xiang, Qingfeng Li, Kaiming Zhuo, Yang Hu, Zhi Yang, Dengtang Liu

  • Open Access

    Serum lipid metabolic characteristics and potential biomarkers in first-episode schizophrenia

    by Suzhen Zhang, Mengyi Luo, Xinping Kuai, Xuan Li, Tianhao Gao, Yuke Dong, Chang Lu, Kaiming Zhuo, Qiong Xiang, Dengtang Liu

    Lipids play a vital role in health and disease, but changes to their circulating levels and the link with schizophrenia remains poorly characterized. This


  • Aberrant prefrontal-hippocampal connectivity of cross-modal associative memory impairment in schizophrenia

    by Zhaolin Zhai, Tianhao Gao, Haixin Cen, Xuan Li, Chang Lu, Yuke Dong, Kaiming Zhuo, Yan Wang, Chunhong Shao, Qiong Xiang, et al.


  • Open Access

    Identifying serum lipidomic signatures related to prognosis in first-episode schizophrenia

    by Mengyi Luo, Suzhen Zhang, Jingxin Xue, Tianhao Gao, Xuan Li, Zhaolin Zhai, Chang Lu, Yuke Dong, Kaiming Zhuo, Qiong Xiang, et al.

    Antipsychotic medications are crucial for alleviating symptoms of schizophrenia (SCZ). However, treatment responses vary across individuals, and few reliable biomarkers currently exist to predict the clinical outcome. Therefore, we aim to identify potential lipid markers for treatment outcomes in patients with first-episode SCZ. Pre-treatment serum samples were obtained from 95 participants who underwent an 8-week treatment regimen with antipsychotic drugs. Untargeted liquid chromatography-mass spectrometry (LC-MS) was used to acquire serum lipidomic profiles, correlating them with treatment responses at 8 weeks to identify potential lipid signatures. The antipsychotic treatment response was quantified using the percentage change on the Positive and Negative Syndrome Scale (PANSS) scale. By combining LASSO regression and Random Forest regression, we identified 8 positively associated and 2 negatively associated baseline lipids related to the PANSS reduction rate. In the further analysis of logistic regression, we identified three candidate lipids, PC (18:2e_19:0), PE (53:7), and TG (16:2e_19:0_20:5), which could together distinguish poor and good responders, with an AUC of 0.805 (95% CI, 0.715–0.894). Our findings suggest that this set of lipid biomarkers may have the potential to predict the outcome of antipsychotic drug treatment. Further validation and larger studies are needed to evaluate their potential for clinical applications. Not applicable.


  • Open Access

    Optimal Treatment of Magnetic Seizure Therapy (MST) in Patients with Clozapine-Resistant Schizophrenia (CRS)

    by Qiong Xiang, Peiwei Xu, Zhaolin Zhai, Yuping Jia, Chunbo Li, Dengtang Liu

    Objective: The study aims to compare the clinical efficacy and cognitive side effect of magnetic seizure therapy (MST) and modified electroconvulsive therapy (MECT) on clozapine resistant schizophrenia (CRS). Methods: Sixteen patients with CRS were enrolled in this randomized, parallel-group, controlled clinical trial. Patients were randomly allocated to receive 10 sessions of add-on MST or MECT over 4 weeks (1:1 ratio) and continued clozapine therapy during the study. Efficacy and neurocognition were assessed at baseline, 4-week and 8-week follow-up. Results: (1) Clinical efficacy: MST significantly improved symptoms of schizophrenia from baseline to 4 weeks, as shown in PANSS total (p = 0.009), PANSS positive (p = 0.026), PANSS negative (p = 0.031) and PANSS general psychopathology (p = 0.023); we also observed significant reductions in PANSS total (p = 0.049) and PANSS positive (p = 0.037) at 8-week follow-up. MECT group also witnessed clinical improvement from baseline to 4-week in PANSS total (p = 0.035) and PANSS positive (p = 0.001); significant reduction in PANSS positive was also observed at 8-week follow-up (p = 0.041). From baseline to 8 weeks, PANSS negative had greater reduction in MST group compared with MECT group (p = 0.042). (2) Neurocognition: Pre-and post-treatment data showed no significant cognitive adverse effects in both groups. Immediate memory is better in patients who received MST than MECT at 4-week follow-up (p = 0.030). Conclusion: In this pilot study, MST and MECT equally improved positive symptoms of CRS, while MST was more effective in relieving negative symptoms. Evidence showed negligible cognitive side effects in MST, with less adverse effect on immediate memory than MECT. As a promising alternative to MECT, MST requires further research in larger clinical population.